Last reviewed 2026-05-26 · How we verify

norepinephrine+vasopressin

norepinephrine+vasopressin is a Vasopressor combination Small molecule drug developed by Peking Union Medical College Hospital. It is currently FDA-approved for Septic shock refractory to fluid resuscitation, Cardiogenic shock, Hypotensive states in critical care settings.

This combination of norepinephrine and vasopressin acts as a dual vasopressor agent that increases blood pressure and tissue perfusion through alpha-adrenergic stimulation and vasopressin V1 receptor activation.

Norepinephrine and vasopressin are small molecule interventions used to treat conditions such as septic shock, vasodilatory shock, sepsis, and shock.

At a glance

Mechanism of action

Norepinephrine is a catecholamine that binds alpha-1 and beta-1 adrenergic receptors to increase vasoconstriction and cardiac contractility. Vasopressin (antidiuretic hormone) activates V1 receptors on vascular smooth muscle to cause vasoconstriction and improve blood pressure. Together, they provide synergistic hemodynamic support in shock states by restoring vascular tone and perfusion pressure.

Approved indications

• Septic shock refractory to fluid resuscitation
• Cardiogenic shock
• Hypotensive states in critical care settings

Common side effects

• Tachycardia
• Arrhythmias
• Tissue ischemia/necrosis at infusion site
• Hypertension
• Decreased urine output

Key clinical trials

• Early Versus Late Adjunctive Vasopressin in Septic Shock (PHASE4)
• Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator
• Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial) (PHASE3)
• Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock (PHASE4)
• Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis (PHASE3)
• Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock (PHASE3)
• Vasoactive Drugs in Intensive Care Unit (PHASE4)
• Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• norepinephrine+vasopressin CI brief — competitive landscape report
• norepinephrine+vasopressin updates RSS · CI watch RSS
• Peking Union Medical College Hospital portfolio CI

Frequently asked questions about norepinephrine+vasopressin

Related

• Drug class: All Vasopressor combination drugs
• Target: All drugs targeting Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, vasopressin V1 receptor
• Manufacturer: Peking Union Medical College Hospital — full pipeline
• Therapeutic area: All drugs in Critical Care / Cardiovascular
• Indication: Drugs for Septic shock refractory to fluid resuscitation
• Indication: Drugs for Cardiogenic shock
• Indication: Drugs for Hypotensive states in critical care settings

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing